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Abstract
Oncologists routinely prescribe chemotherapy for patients with advanced cancer. This practice is sometimes
misunderstood by palliative care clinicians, yet data clearly show that chemotherapy can be a powerful palliative
intervention when applied appropriately. Clarity regarding the term “palliative chemotherapy” is needed: it is
chemotherapy given in the non-curative setting to optimize symptom control, improve quality of life, and sometimes
to improve survival. Unfortunately, oncologists lack adequate tools to predict which patients will benefit. In a study
recently published in BMC Palliative Care, Creutzfeldt et al. presented an innovative approach to advancing the science
in this area: using patient reported outcomes to predict responses to palliative chemotherapy. With further research,
investigators may be able to develop predictive models for use at the bedside to inform clinical decision-making about
the risks and benefits of treatment. In the meantime, oncologists and palliative care clinicians must work together to
reduce the use of “end-of-life chemotherapy”—chemotherapy given close to death, which does not improve longevity
or symptom control—while optimizing the use of chemotherapy that has true palliative benefits for patients.
Oncologists routinely prescribe chemotherapy for pa-
tients with advanced, incurable cancer. This practice is
sometimes misunderstood by palliative care clinicians,
who tend not to see the many patients who routinely
benefit from this “palliative intent” chemotherapy, in-
stead being called to evaluate those who are admitted to
the hospital with complications or who are generally
faring poorly. Yet there are clear data demonstrating that
chemotherapy itself can be a powerful palliative inter-
vention when applied appropriately. Clarification regard-
ing the term palliative chemotherapy is critical:
palliative chemotherapy is defined as chemotherapy that
is given in the non-curative setting to optimize symptom
control, improve quality of life (QoL) and, ideally, to im-
prove survival.
Evidence demonstrates that palliative chemotherapy
has an established role and effectively achieves these
aims for select patients with a variety of metastatic solid
tumors. For example, chemotherapy can improve pain,
physical function, and longevity in patients with ad-
vanced pancreatic cancer, while slowing the rate of de-
cline in appetite and the onset of bothersome symptoms
like dyspnea and constipation [1, 2]. Similarly, “targeted”
biologic therapy can significantly improve pain, dyspnea,
and cough in patients with advanced non-small cell lung
cancer [3] and QoL and fatigue in breast cancer [4].
Many other such examples exist in the oncology litera-
ture, clearly supporting the role chemotherapy has in
improving or maintaining a patient’s QoL and address-
ing troublesome symptoms.
Despite our best efforts, however, oncologists some-
times get these decisions wrong, and thereby either
over-treat a patient who is near death (and thus unlikely
to benefit from chemotherapy), or under-treat a patient
who might derive real palliative benefits from chemo-
therapy. While professional organizations such as the
American Society of Clinical Oncology (ASCO) have
recommendations to aid oncologists’ decision-making
about the appropriateness of chemotherapy in patients
with advanced cancer [5], the data to guide these de-
cisions remain woefully inadequate. Research in this
area is sorely needed, and is nicely embodied in the
work of Creutzfeldt et al. recently published in BMC
Palliative Care [6].
This line of research is particularly relevant given
renewed interest in the appropriate role of chemother-
apy in advanced cancer settings. In an analysis of data
from the “Coping with Cancer Study,” Prigerson et al.
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recently published findings that challenge a central tenet
of palliative chemotherapy prescribing: the notion that
patients with good performance status are those most
likely to benefit [7]. To the contrary, in this study
chemotherapy was actually associated with worse QoL
in more functional patients in the last week of life, and
was also not associated with improved longevity. These
findings have led some to conclude that patients with
advanced cancer should not be offered palliative chemo-
therapy at all, or that the concept of “palliative chemo-
therapy” is nonsensical. To be clear, these conclusions
reflect a misapplication of the study’s findings, and an
over-interpretation of the data.
As dual-trained palliative care physicians and medical
oncologists, we are particularly sensitive to both sides of
this debate, and have been dismayed to hear some of our
palliative care colleagues make broad anti-chemotherapy
statements following the publication of the Prigerson
et al. article. We know that such statements ignore de-
cades of evidence demonstrating clear palliative benefits
of chemotherapy in appropriately-selected patients with
advanced cancer, and also ignores some of the important
limitations of this study, which did not assess symptoms
or QoL during the receipt of chemotherapy (precisely
the measures shown to improve in most studies of pal-
liative chemotherapy). We also must note that blanket
criticisms of palliative chemotherapy are divisive, and
even insulting to oncologists’ good intentions when pre-
scribing palliative chemotherapy.
Rather, we should encourage more collaboration be-
tween palliative care and oncology, in light of the many
recent demonstrations of improved outcomes resulting
from earlier, concurrent palliative care as part of cancer
care (even alongside chemotherapy) [8–12]. Rather than
drive a wedge between our disciplines, these recent find-
ings should motivate and prompt us to elevate the state
of the science to address the difficult clinical challenge
at hand: how to identify which patients are most likely
to benefit from palliative chemotherapy versus those
who may actually be harmed by it.
As recently published in BMC Palliative Care, Creutuz-
feldt and colleagues present an innovative and important
approach to advancing the science in this area: using
patient reported outcomes (PROs) to predict responses to
palliative chemotherapy [6]. Here, the investigators
evaluated the predictive value of pretreatment QoL and
symptom burden for patients receiving palliative chemo-
therapy. They did so in part by utilizing published esti-
mates of response rates and survival, thereby allowing
them to explore whether pre-treatment variables might
predict the likelihood of benefitting from treatment.
Ultimately, the investigators found that while palliative
chemotherapy was often helpful, certain baseline fea-
tures were associated with its impact on treatment
outcomes. For example, patients with worse QoL and
symptom burden at baseline were less likely to benefit,
while those with better physical functioning were more
likely to have objective tumor responses by imaging cri-
teria. Perhaps more interesting, however, is the finding
that overall global health status (as measured by the
EORTC scale) improved with treatment, even among
those cases where survival was not improved. Interest-
ingly, even patients who had no objective tumor re-
sponse by imaging experienced improved QoL and
symptom burden with palliative chemotherapy. These
findings resonate with oncologists’ motivations for pre-
scribing chemotherapy with palliative intent: where its
goal is sometimes just to help patients live better, even
if life is not prolonged.
While these findings must be tested in larger, more ro-
bust study designs, they present preliminary data for cli-
nicians currently facing difficult decisions about whether
to recommend a course of palliative chemotherapy. With
further research in this area, investigators may be able to
develop predictive models that can be used at the bed-
side to inform clinical decision-making about the risks
and benefits of chemotherapy for an individual patient
with advanced, incurable disease. This is a great first
step in an important line of research that has great po-
tential to improve clinical care.
While we wait for evidence to develop further in the
area, however, we must advise more clarity in our ter-
minology. Palliative chemotherapy is treatment that is
given in the non-curative setting to optimize symptom
control, improve or maintain QoL and, ideally, to also
improve survival. We should separate this concept
from one that is far less controversial: “end-of-life
chemotherapy.” Here, we refer to chemotherapy that
is given close to death, which does not improve lon-
gevity and likely also has no benefits in relieving
symptoms or improving QoL; indeed it may even
worsen survival or symptoms.
Whether oncologist or palliative care clinician, our
shared goal should be to reduce the use of “end-of-life
chemotherapy” while optimizing the use of chemother-
apy that has true palliative benefits for patients. In other
words, we must be careful not to throw the proverbial
baby out with the bathwater. Indeed, palliative care spe-
cialists must be particularly careful not to assume the
role of “anti-chemo police” as we continue building
models of concurrent care and effective collaboration.
Chemotherapy continues to have an appropriate role
in palliating symptoms among selected patients with
advanced cancer, and we thank Creutzfeldt et al. for
providing another example of how palliative care and
oncology can learn from each other to address our
mutual goal – improving the lives of patients facing a
serious illness.
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